DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based ...

AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.

The $30 million facility was made possible, in part, through a $4 million contribution through the AdventHealth Palm Coast ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

Relay Therapeutics (market cap: $748.2 million), a biotechnology company focused on developing innovative cancer therapies, has been making significant strides in the competitive landscape of ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.

The American Cancer Society has released its latest report on cancer in the United States, revealing both encouraging and concerning trends.

Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. This emerging technology holds ...

Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...